PMID- 16415713
OWN - NLM
STAT- MEDLINE
DCOM- 20070403
LR  - 20221207
IS  - 0271-0749 (Print)
IS  - 0271-0749 (Linking)
VI  - 26
IP  - 1
DP  - 2006 Feb
TI  - Treatment of chronic posttraumatic stress disorder in combat veterans with 
      citalopram: an open trial.
PG  - 84-8
AB  - Posttraumatic stress disorder (PTSD) is a serious mental illness which exhibits 
      significant impairment of psychosocial and occupational function. At present, 
      serotonin reuptake inhibitors (SRIs) show therapeutic promise for the treatment 
      of PTSD. However, results in the veteran population have been less robust or 
      often negative. In this study, a relatively new and the most selective SRI, 
      citalopram, was evaluated for the treatment of PTSD. Veterans with chronic PTSD 
      (N = 18) were enrolled in an 8-week open trial of citalopram after providing 
      written informed consent. The primary outcome measures were the 
      Clinician-Administered PTSD Scale (CAPS), the Hamilton Rating Scale for Anxiety 
      (HAM-A), and the Clinical Global Impression Scale (CGI). Seventeen patients 
      completed at least 4 weeks of the 8-week trial. During treatment, there was a 
      moderate response with 42% of patients demonstrating a > or =30% reduction in 
      total CAPS score at week 8. Comparable results were demonstrated in the Hamilton 
      Depression Rating Scale (HAM-D), HAM-A, Global Assessment of Function (GAF), and 
      CGI rating scales. In a follow-up analysis, a treatment effect was shown for CAPS 
      B at week 4, but was not sustained at week 8. Overall, citalopram was generally 
      well tolerated with reported adverse events being benign in nature. These pilot 
      results demonstrate a moderate effect of citalopram in the treatment of 
      combat-induced PTSD. However, the sample size was small and patient population is 
      limited to veterans with combat-induced PTSD. Further study in a larger and more 
      diverse patient sample is warranted prior to final conclusions on efficacy of 
      citalopram for the treatment of PTSD.
FAU - English, Brett A
AU  - English BA
AD  - Department of Pharmacology, Center for Molecular Neuroscience, Graduate Program 
      in Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA. 
      brett.english@vanderbilt.edu
FAU - Jewell, Michele
AU  - Jewell M
FAU - Jewell, George
AU  - Jewell G
FAU - Ambrose, Sandra
AU  - Ambrose S
FAU - Davis, Lori L
AU  - Davis LL
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - Aged
MH  - Citalopram/*therapeutic use
MH  - Combat Disorders/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Selective Serotonin Reuptake Inhibitors/*therapeutic use
MH  - Stress Disorders, Post-Traumatic/*drug therapy
MH  - Treatment Outcome
MH  - Veterans
EDAT- 2006/01/18 09:00
MHDA- 2007/04/04 09:00
CRDT- 2006/01/18 09:00
PHST- 2006/01/18 09:00 [pubmed]
PHST- 2007/04/04 09:00 [medline]
PHST- 2006/01/18 09:00 [entrez]
AID - 00004714-200602000-00018 [pii]
AID - 10.1097/01.jcp.0000195043.39853.bc [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2006 Feb;26(1):84-8. doi: 
      10.1097/01.jcp.0000195043.39853.bc.